...
机译:新型抗癌化合物,用于开发靶向抗失语症肿瘤的组合疗法
Department of Diabetes and Metabolic Diseases Research Beckman Research Institute, City of Hope, National Medical Center, Duarte, California, 91010, USA;
Department of Molecular Biology and Immunology, University of North Texas Health Science Center, Fort Worth, Texas, 76107, USA;
Department of Diabetes and Metabolic Diseases Research Beckman Research Institute, City of Hope, National Medical Center, Duarte, California, 91010, USA;
Department of Diabetes and Metabolic Diseases Research Beckman Research Institute, City of Hope, National Medical Center, Duarte, California, 91010, USA;
Department of Diabetes and Metabolic Diseases Research Beckman Research Institute, City of Hope, National Medical Center, Duarte, California, 91010, USA;
anoikis; drug-resistance; metastases; network-targeted cancer therapeutics;
机译:新型抗癌化合物,可用于开发针对靶向抗厌食症的肿瘤的组合疗法。
机译:组合微环境对单个途径靶向的抗癌化合物施加连续的细胞反应
机译:开发一系列用于结合靶点和免疫疗法的Kras / P53复合突变小鼠同种异体移植肿瘤模型
机译:运铁蛋白-PEG脂质体将〜(10)B化合物定位为固体肿瘤以进行硼中子捕获治疗(BNCT)
机译:线粒体是类癌中抗癌治疗的潜在靶点吗?
机译:组合微环境对单途径靶向的抗癌化合物施加了连续的细胞反应
机译:组合微环境对单一途径靶向抗癌化合物的细胞反应的连续性
机译:基于抗体的免疫疗法和节律化疗联合靶向前列腺癌细胞和肿瘤相关周细胞